In this video, health-care analyst David Williamson discusses Dendreon's recent third-quarter results. This video focuses on the good news in the report, as a number of positive trends have moved in Dendreon's favor. Watch and find out what made investors bid up shares as much as 30% intraday on Friday.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Investors Are Excited About Dendreon's Earnings originally appeared on Fool.com.David Williamson owns shares of Johnson & Johnson and Dendreon. Follow him on Twitter, @MotleyDavid. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.